| Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway KJ Kurppa, Y Liu, C To, T Zhang, M Fan, A Vajdi, EH Knelson, Y Xie, ... Cancer cell 37 (1), 104-122. e12, 2020 | 333 | 2020 |
| Single and dual targeting of mutant EGFR with an allosteric inhibitor C To, J Jang, T Chen, E Park, M Mushajiang, DJH De Clercq, M Xu, ... Cancer discovery 9 (7), 926-943, 2019 | 249 | 2019 |
| Mutant‐selective allosteric EGFR degraders are effective against a broad range of drug‐resistant mutations J Jang, C To, DJH De Clercq, E Park, CM Ponthier, BH Shin, ... Angewandte Chemie 132 (34), 14589-14597, 2020 | 95 | 2020 |
| The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice C To, EH Kim, DB Royce, CR Williams, RM Collins, R Risingsong, ... Cancer Prevention Research 7 (7), 698-707, 2014 | 85 | 2014 |
| EGFR-mutated lung cancers resistant to osimertinib through EGFR C797S respond to first-generation reversible EGFR inhibitors but eventually acquire EGFR T790M/C797S in … D Rangachari, C To, JE Shpilsky, PA VanderLaan, SS Kobayashi, ... Journal of Thoracic Oncology 14 (11), 1995-2002, 2019 | 77 | 2019 |
| An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer C To, TS Beyett, J Jang, WW Feng, M Bahcall, HM Haikala, BH Shin, ... Nature cancer 3 (4), 402-417, 2022 | 75 | 2022 |
| Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung … C To, CS Ringelberg, DB Royce, CR Williams, R Risingsong, MB Sporn, ... Carcinogenesis 36 (7), 769-781, 2015 | 69 | 2015 |
| Discovery and optimization of dibenzodiazepinones as allosteric mutant-selective EGFR inhibitors DJH De Clercq, DE Heppner, C To, J Jang, E Park, CH Yun, ... ACS medicinal chemistry letters 10 (11), 1549-1553, 2019 | 63 | 2019 |
| Synthetic triterpenoids target the Arp2/3 complex and inhibit branched actin polymerization C To, BH Shilton, GM Di Guglielmo Journal of Biological Chemistry 285 (36), 27944-27957, 2010 | 49 | 2010 |
| Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors TS Beyett, C To, DE Heppner, JK Rana, AM Schmoker, J Jang, ... Nature communications 13 (1), 2530, 2022 | 39 | 2022 |
| The synthetic triterpenoid 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid-imidazolide alters transforming growth factor β-dependent signaling and cell migration by affecting … C To, S Kulkarni, T Pawson, T Honda, GW Gribble, MB Sporn, JL Wrana, ... Journal of Biological Chemistry 283 (17), 11700-11713, 2008 | 36 | 2008 |
| Discovery of a potent dual ALK and EGFR T790M inhibitor J Jang, JB Son, C To, M Bahcall, SY Kim, SY Kang, M Mushajiang, Y Lee, ... European journal of medicinal chemistry 136, 497-510, 2017 | 35 | 2017 |
| Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. Cancer Discov. 2019; 9 (7): 926-43. doi: 10.1158/2159-8290 C To, J Jang, T Chen, E Park, M Mushajiang, DJH De Clercq, M Xu, ... CD-18-0903, 0 | 24 | |
| Design of a “two-in-one” mutant-selective epidermal growth factor receptor inhibitor that spans the orthosteric and allosteric sites F Wittlinger, DE Heppner, C To, M Günther, BH Shin, JK Rana, ... Journal of medicinal chemistry 65 (2), 1370-1383, 2021 | 18 | 2021 |
| Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer PÖ Eser, RM Paranal, J Son, E Ivanova, Y Kuang, HM Haikala, C To, ... Science translational medicine 13 (609), eabb3738, 2021 | 14 | 2021 |
| Synthetic triterpenoids inhibit GSK3β activity and localization and affect focal adhesions and cell migration C To, A Roy, E Chan, MAM Prado, GM Di Guglielmo Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1864 (7), 1274-1284, 2017 | 13 | 2017 |
| Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC TW Gero, DE Heppner, TS Beyett, C To, SC Azevedo, J Jang, T Bunnell, ... Bioorganic & medicinal chemistry letters 68, 128718, 2022 | 11 | 2022 |
| Allosteric inhibition of drug resistant forms of EGFR L858R mutant NSCLC C To, TS Beyett, J Jang, WW Feng, M Bahcall, HM Haikala, BH Shin, ... Nature cancer 3 (4), 402, 2022 | 5 | 2022 |
| PARP inhibitors for chemoprevention—Reply C To, MB Sporn, KT Liby Cancer Prevention Research 7 (11), 1172-1172, 2014 | 3 | 2014 |
| Pharmaceutical combinations of egfr inhibitors and methods of use thereof NS Gray, D De Clercq, J Jaebong, P Janne, C To, M Eck, P Eunyoung US Patent App. 16/970,860, 2021 | 2 | 2021 |
